Akut-auf-chronisches Leberversagen: Neue Definition eines komplexen Krankheitsbildes

Zusammenfassung

Das akut-auf-chronische Leberversagen (ACLF) ist durch eine plötzlich auftretende Dekompensation einer vorbestehenden Lebererkrankung mit Organversagen und hoher Kurzzeitmortalität gekennzeichnet. Die Patienten unterscheiden sich in Bezug auf das prädisponierende Stadium der Lebererkrankung, die Auslöser und den Verlauf des Organversagens. Ein kürzlich erreichter Konsens einer einheitlichen Arbeitsdefinition und Klassifikation stellt die Grundlage zur weiteren Erforschung dieses Krankheitsbildes dar, um pathophysiologische Mechanismen zu verstehen, diagnostische und prognostische Biomarker zu etablieren, und um risikoadaptierte Behandlungsstrategien zu implementieren.

Abstract

Acute-on-chronic liver failure (ACLF) is characterized by a sudden onset of decompensation in patients with preexisting liver disease followed by subsequent organ failure and high short-term mortality. ACLF is extremely heterogeneous in terms of predisposing stage of liver disease, precipitating events, and the course of organ failure and has been defined differently by different medical associations in the East and in the West. A recent consensus working definition is the basis for further research in order to understand underlying pathophysiological mechanisms, to establish diagnostic and prognostic biomarkers, and to implement risk-adapted treatment strategies.

Schlüsselwörter

akut-auf-chronisches Leberversagen - Organversagen - Leberzirrhose

Keywords

acute-on-chronic liver failure - organ failure - liver cirrhosis

• Literatur

• 1 Moreau R, Jalan R, Gines P et al. Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology 2013; 144: 1426-1437.e9
• 2 Wlodzimirow KA, Eslami S, Abu-Hanna A et al. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. Liver Int 2013; 33: 40-52
• 3 Jalan R, Yurdaydin C, Bajaj JS et al. Toward an improved definition of acute-on-chronic liver Failure. Gastroenterology 2014; 147: 4-10
• 4 Sarin SK, Kedarisetty CK, Abbas Z et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8: 453-471
• 5 Shi Y, Yang Y, Hu Y et al. Acute-on-chronic liver failure precipitated by hepatic injury is distinct from that precipitated by extrahepatic insults. Hepatology 2015; 62: 232-242
• 6 Kim TY, Song DS, Kim HY et al. Characteristics and Discrepancies in Acute-on-Chronic Liver Failure: Need for a Unified Definition. PloS One 2016; 11: e0146745
• 7 Belcher JM, Garcia-Tsao G, Sanyal AJ et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 2013; 57: 753-762
• 8 Wong F, O’Leary JG, Reddy KR et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 2013; 145: 1280-1288.e1
• 9 Bruns T, Reuken PA, Stengel S et al. The Prognostic Significance Of Bacterial DNA In Patients With Decompensated Cirrhosis and Suspected Infection. Liver Int 2016; DOI: 10.1111/liv.13095.
• 10 Bernsmeier C, Pop OT, Singanayagam A et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015; 148: 603-615.e14
• 11 O’Brien AJ, Fullerton JN, Massey KA et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med 2014; 20: 518-523
• 12 Jalan R, Saliba F, Pavesi M et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-1047
• 13 Gustot T, Fernandez J, Garcia E et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology 2015; 62: 243-252
• 14 Grønbæk H, Rødgaard-Hansen S, Aagaard NK et al. The soluble macrophage activation markers sCD163 and Mannose Receptor (sMR) predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF). J Hepatol 2015; DOI: 10.1016/j.jhep.2015.11.021.
• 15 Zimmermann HW, Reuken PA, Koch A et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med 2013; 274: 86-100
• 16 Bañares R, Nevens F, Larsen FS et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57: 1153-1162
• 17 Mookerjee RP, Pavesi M, Thomsen KL et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 2016; 64: 574-582
• 18 Chavez-Tapia NC, Mendiola-Pastrana I, Ornelas-Arroyo VJ et al. Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis. Ann Hepatol 2015; 14: 631-641